DiscoverPharmacy FocusS2 Ep59: Taletrectinib Takes Aim: A New Chapter in ROS1-Positive NSCLC
S2 Ep59: Taletrectinib Takes Aim: A New Chapter in ROS1-Positive NSCLC

S2 Ep59: Taletrectinib Takes Aim: A New Chapter in ROS1-Positive NSCLC

Update: 2025-07-30
Share

Description

Kevin Chen, PharmD, MS, BCOP, CPP, and Amanda Cass, PharmD, BCPS, BCOP, share key insights about ROS1, non-small cell lung cancer, and the new approved drug taletrectinib.




Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

S2 Ep59: Taletrectinib Takes Aim: A New Chapter in ROS1-Positive NSCLC

S2 Ep59: Taletrectinib Takes Aim: A New Chapter in ROS1-Positive NSCLC

Pharmacy Times